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Background: Diabetus mellitus (DM) is a key risk factor for chronic kidney disease (CKD). In aspirin treated DM patients the presence of 
moderate/severe CKD is associated with reduced clinical efficacy of adjunctive clopidogrel therapy. If these findings may be attributed to differences 
in clopidogrel-induced effects is unknown. We sought to assess the impact of renal function on platelet reactivity in patients with DM and coronary 
artery disease on aspirin and clopidogrel therapy.
Methods: This was a cross-sectional observational study in which DM patients on maintenance aspirin and clopidogrel therapy were studied. 
Patients were categorized into two groups according to the presence or absence of moderate/severe CKD. Platelet aggregation following adenosine 
diphosphate (ADP) and collagen stimuli were assessed using light transmittance aggregometry and defined patients with high post-treatment 
platelet reactivity (HPPR). Markers of platelet activation, including glycoprotein IIb/IIIa activation and P-selectin expression, using flow cytometry 
were also determined.
Results: A total of 306 DM patients were analyzed. Patients with moderate/severe CKD (n=84) had significantly higher ADP (60±13% vs. 52±15%, 
p = 0.001) and collagen (49±20% vs. 41±20%, p = 0.004)-induced platelet aggregation compared to those without (n=222). After adjustment 
for potential confounders, patients with moderate/severe CKD were more likely to have HPPR following ADP [adjusted odds ratio (OR) 3.8, 95% 
confidence intervals (CI) 1.7-8.5, p = 0.001] and collagen (adjusted OR 2.4; 95% CI, 1.1-5.4; p=0.029) stimuli. Markers of platelet activation were 
significantly increased in patients with HPPR.
Conclusions: In DM patients with coronary artery disease on maintenance aspirin and clopidogrel therapy, impaired renal function is associated 
with reduced clopidogrel-induced antiplatelet effects and a greater prevalence of HPPR.
